Pulmonary hypertension (PH) is a debilitating disease with a poor prognosis. Therapeutic
options remain limited despite the introduction of prostacyclin analogues, endothelin …

Therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last
decades. The advent of pharmacological therapies targeting the prostacyclin, endothelin …

Importance of the field: Pulmonary arterial hypertension (PAH) is a clinical syndrome
characterized by structural narrowing of the small pulmonary arteries that often culminates in …

Past medical therapy for pulmonary arterial hypertension included the use of calcium-
channel antagonists in acute vasoreactive subjects and oral anticoagulants and continuous …

Importance of the field: Treatments of pulmonary arterial hypertension (PAH) that have so far
proven efficacious are all based on the restoration of endothelium control of pulmonary …

Pulmonary hypertension (mean pulmonary arterial pressure> 20mm Hg at rest or> 30mm Hg
during exercise) occurs (i) as primary pulmonary hypertension (no known underlying …

May 5th signals World Pulmonary Hypertension Day and whilst the world is 20 currently
focussing on the coronavirus pandemic, it is important to remember 21 our patients with this …

Until 20 years ago the treatment of pulmonary arterial hypertension (PAH) was based on
case reports and small series, and was largely ineffectual. As a deeper understanding of the …

Pulmonary arterial hypertension is a progressive, fatal disease. Current treatments including
prostanoids, endothelin-1 (ET-1) antagonists, and phosphodiesterase (PDE) inhibitors, have …

Pulmonary hypertension (PH) is a progressive and often fatal illness presenting with
nonspecific symptoms of dyspnea, lower extremity edema, and exercise intolerance …